SUMMARY

• Perseris (risperidone) and Uzedy (risperidone) are not Janssen products.^1,2
• Perseris and Uzedy are subcutaneous, long-acting injectables available as once monthly and once monthly or once every 2 months, respectively.^1,2
• There are currently no head-to-head studies examining the efficacy and safety of INVEGA SUSTENNA or INVEGA TRINZA compared to the once monthly or once every
  2 months subcutaneous risperidone injections.^3,4
• The subcutaneous risperidone injections are not substitutable generics for any product currently on the market.

BACKGROUND

Perseris (90 mg or 120 mg) is administered once-monthly in the abdomen or back of the upper arm by a healthcare professional and is indicated for the treatment of schizophrenia in adults.¹

Uzedy (50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 200 mg, and 250 mg) is administered as either a once monthly or a once every 2 month in the abdomen or upper arm via subcutaneous injection by a healthcare professional. Uzedy is indicated for the treatment of schizophrenia in adults.²

For questions on these products, please refer to the respective manufacturer.

INVEGA SUSTENNA (39 mg, 78 mg, 117 mg, 156 mg, and 234 mg) is a 1-month intramuscular deltoid or gluteal injection administered by a healthcare professional. INVEGA SUSTENNA is indicated in adults for the treatment of schizophrenia and for schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants.³

INVEGA TRINZA (273 mg, 410 mg, 546 mg, or 819 mg) is a 3-month intramuscular deltoid or gluteal injection administered by a healthcare professional. INVEGA TRINZA is indicated for the treatment of schizophrenia in adults after they have been adequately treated with INVEGA SUSTENNA for at least four months.⁴

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, DERWENT^® (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 09 April 2024.